Prosecution Insights
Last updated: April 19, 2026
Application No. 17/962,656

Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof

Non-Final OA §102§112
Filed
Oct 10, 2022
Examiner
SEAMAN, D MARGARET M
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of Colorado
OA Round
3 (Non-Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
2y 4m
To Grant
84%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allow Rate
1063 granted / 1387 resolved
+16.6% vs TC avg
Moderate +8% lift
Without
With
+7.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
20 currently pending
Career history
1407
Total Applications
across all art units

Statute-Specific Performance

§101
3.7%
-36.3% vs TC avg
§103
15.1%
-24.9% vs TC avg
§102
24.3%
-15.7% vs TC avg
§112
33.9%
-6.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1387 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application was filed 10/10/2022 and is a CIP of 16/760815 (04/330/2020) now US Pat 11466010 which is a 371 of PCT/US18/58286 (10/30/2018) which claims priority to PRO 62/579015 (10/30/2017). RCE papers were filed 12/19/2025 with an amendment and argument. Claims 1-24 are before the Examiner. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. The rejection of claims 1, 2, 4 and 8 under 35 U.S.C. 102(a)(1) as being anticipated by Zhang, as stated in paper dated 09/30/2025, is upheld. Specifically on page 62 PNG media_image1.png 170 156 media_image1.png Greyscale second compound where R=OH anticipates the instant claims. This compound fully anticipate the instant claims. Applicant argues in paper dated 12/19/2025 that the amendments to claim 1 overcome the rejection of record. However, that is not the case. The two compounds taught by Zhang where the above pictured R is OH anticipates the instant claims. For the instant claims 1, 2, 4 and 8…X=C, X’=N, R1is OH, R2, R3 and R5=H and R4=OH. The proviso in claim 1 reads…when R1is either H or alkoxy then R4 is alkoxy. However, R1=OH is not within the scope of the proviso since R1 is neither H or alkoxy. Due to this, the rejection is upheld. Claim Rejections - 35 USC § 112 The rejection of claim 1 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as stated I paper dated 09/30/2025, is withdrawn in view of applicants amendments in paper dated 12/19/2025. Claim Objections Claims 3, 5-7 and 9-12 are objected to because of the following informalities: These claims depend from a rejected base claim but would be allowable if rewritten in independent form free of the above cited rejections. Appropriate correction is required. Allowable Subject Matter Claims 13-24 are free of prior art and are allowed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to D MARGARET M SEAMAN whose telephone number is (571)272-0694. The examiner can normally be reached M-F 8am-4pm Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D MARGARET M SEAMAN/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Oct 10, 2022
Application Filed
Jun 11, 2025
Non-Final Rejection — §102, §112
Sep 13, 2025
Response Filed
Sep 25, 2025
Final Rejection — §102, §112
Dec 19, 2025
Request for Continued Examination
Dec 22, 2025
Response after Non-Final Action
Dec 23, 2025
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599135
A COMPOSITION AND METHOD FOR PREPARING N-PHENYLPYRAZOLE-1-CARBOXAMIDES
2y 5m to grant Granted Apr 14, 2026
Patent 12595234
Bioactive Benzocycloheptene Analogues From Himachalenes and its Applications
2y 5m to grant Granted Apr 07, 2026
Patent 12595239
SUBSTITUTED ISOXAZOLINE DERIVATIVES
2y 5m to grant Granted Apr 07, 2026
Patent 12590072
THYROMIMETICS
2y 5m to grant Granted Mar 31, 2026
Patent 12577207
INDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR PARTIAL AGONISTS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
84%
With Interview (+7.9%)
2y 4m
Median Time to Grant
High
PTA Risk
Based on 1387 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month